CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Fresenius Kabi Oncology Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Fresenius Kabi Oncology Ltd
Echelon Institutional Area
Plot No-11, Sector - 32
Phone: +91 1244885000p:+91 1244885000 GURGAON, 122001  India Ticker: 532545532545

Business Summary
Fresenius Kabi Oncology Limited is an India-based company, which is engaged in manufacturing of generic pharmaceutical products. The Company develops, manufactures and markets anti-cancer products. Its segments include Formulation, Bulk Drug and R&D. Its products include active pharmaceutical ingredients (APIs) and finished dosage products. Its APIs include cytotoxic, cytostatic, anesthetics and drug intermediates. Its APIs include Anastrazole, Bicalutamide, Decitabine, Bendamustine, Imatinib Mesylate, Bupivacaine, Levobupivacaine, Ropivacaine and Metaxalone. Its dosage forms include Paclitaxel Injection, Gemcitabine Injection, Oxaliplatin Injection, Methotrexate Injection, Irinotecan Injection, Letrozole Tablets, Bicalutamide Tablets, Vinorelbine Injection, Etoposide Injection, Fluorouracil Injection and Bicalutamide Tablets. Its ready-to-use finished products are manufactured for and marketed in India, European Union, Australia, the United States, Canada, Mexico and Russia.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20193/31/2019Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Financial Officer Maria M.Karvin 42 5/27/2013 5/27/2013
Compliance Officer, Company Secretary, Head - legal NikhilKulshreshtha 46
Chairman of the Board, Managing Director Peter F.Nilsson 49 1/1/2014 10/20/2011
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Fresenius Kabi Oncology Plc Lion Court, Farnham Road Hampshire SRY United Kingdom

Business Names
Business Name
532545
Dabur Pharma Limited
FKONCO
Fresenius Kabi Oncology Ltd
Fresenius Kabi Oncology Plc
Fresenius Kabi Oncology US Inc.

General Information
Number of Employees: 1,152 (As of 3/31/2013)
Outstanding Shares: 170,247,857 (As of 3/31/2019)
Shareholders: 44,333
Stock Exchange: NSE
Fax Number: +91 1244885003


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 06, 2019